The immune system's activation during infection or injury is heavily studied — the signaling cascades that recruit monocytes, trigger cytokine release, and amplify the inflammatory response are well-characterized. How inflammation resolves — how the system turns off — has received far less attention, treated as a passive process: remove the stimulus, and the response fades. Published in Nature Communications, a study from University College London demonstrates that resolution is not passive. It is an active biochemical program mediated by fat-derived molecules called epoxy-oxylipins.
The experiment used controlled inflammation in human volunteers. UV-killed E. coli bacteria injected into the forearm triggered a measurable immune response — pain, swelling, monocyte recruitment. When researchers administered a drug (GSK2256294) that blocks the enzyme soluble epoxide hydrolase (sEH) — an enzyme that normally degrades epoxy-oxylipins — the inflammatory response resolved faster. Pain decreased sooner. Intermediate monocytes, the immune cells most strongly linked to chronic inflammatory disease, declined significantly in both blood and tissue.
The mechanism is specific: one epoxy-oxylipin, 12,13-EpOME, shuts down p38 MAPK, a signaling protein that drives monocyte transformation from anti-inflammatory to pro-inflammatory phenotype. The off-switch doesn't suppress immunity globally. It targets the transition point where acute inflammation becomes chronic. The enzyme sEH normally degrades the off-switch molecules, maintaining a balance between activation and resolution. In chronic disease, the balance tilts toward activation — not because the on-switch is too strong, but because the off-switch is being destroyed too quickly.
The structural insight is about the symmetry of biological control. Every engineered control system has both an actuator and a brake. The inflammatory system has both too — but medical research has overwhelmingly studied the actuator. Anti-inflammatory drugs suppress the on-signal (NSAIDs block prostaglandins, steroids suppress cytokines). The epoxy-oxylipin result suggests an alternative: instead of suppressing activation, amplify the resolution that's already built in. Protect the off-switch rather than fighting the on-switch.